Maimendong and Qianjinweijing Tang combined with cisplatin suppressed lung cancer through targeting lncRNA-p21

被引:2
|
作者
Xie, Meiping [1 ,2 ]
Wang, Cheng [1 ,2 ]
Sun, Yuxia [1 ,2 ]
Mao, Qiuyuan [1 ,2 ]
Sun, Shasha [1 ,2 ]
Wu, Mianhua [2 ]
Zhu, Jiapeng [1 ]
Li, Wenting [2 ,3 ]
Jiang, Zequn [1 ,2 ,3 ]
机构
[1] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, 138 Xianlin Rd, Nanjing 210023, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Tradit Chinese Med, 138 Xianlin Rd, Nanjing 210023, Peoples R China
[3] Nanjing Univ Chinese Med, 138 Xianlin Rd, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
Jin formula; Cisplatin; Lung cancer; lncRNA-p21; MAPK; NONCODING RNA;
D O I
10.1016/j.jep.2023.117547
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Maimendong and Qianjinweijing Tang (Jin formula) is a traditional Chinese medicine formula that has been proven effective in the treatment of lung cancer in long-term clinical practice. Aim of the study: To evaluate the anti-tumor effects of Jin formula combined with cisplatin (JIN + DDP) in vivo and in vitro, as well as to explore the role of long non-coding RNA (lncRNA) in the anti-lung cancer mechanism of its action. Materials and methods: A Lewis lung cancer model was established in C57 BL/6 mice to study the in vivo antitumor effect of Jin formula combined with cisplatin. TUNEL staining and western blot were applied to study the effects of Jin formula combined cisplatin on apoptosis. The in vitro anti-cancer function of Jin formula combined with cisplatin was explored by cell viability assay, flow cytometry, wound healing assay and transwell assay. The changes in lncRNA expression profiles were determined by lncRNA microarray, and the differentially expressed lncRNA-p21 was verified by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis. The expression differences of lncRNA-p21 in tumor and normal tissues were analyzed by bioinformatics, and the expression differences of lncRNA-p21 in tumor cells and normal cells were detected by qRT-PCR. The role of lncRNA-p21 in the anti-cancer effect of Jin formula combined cisplatin was investigated by knockdown or overexpression of lncRNA-p21 and a series of cell experiments. The expression of MAPK pathway-related proteins was analyzed by western blot. Results: Jin formula combined with cisplatin (JIN + DDP) can suppress tumor growth and promote apoptosis in Lewis lung cancer mouse model. LncRNA-p21 was significantly up-regulated in the JIN and JIN + DDP groups, and the expression of lncRNA-p21 in lung cancer tissues and cells was lower than that in normal tissues and cells. In vitro, JIN + DDP significantly induced apoptosis and inhibited the proliferation, migration, and invasion of H460 and H1650 lung cancer cells. The above effects can be enhanced by the overexpression of lncRNA-p21 and eliminated by knock-down of lncRNA-p21. Further studies revealed that JIN + DDP inhibited the expression of mitogen-activated protein kinase (MAPK) pathway-related proteins, whereas knock-down of lncRNA-p21 abrogated the inhibition of the MAPK signaling pathway. Conclusions: This study showed that Jin formula combined with cisplatin could effectively inhibit the progression of lung cancer partially through targeting lncRNA-p21.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Maimendong and Qianjinweijing Tang (Jin formula) suppresses lung cancer by regulation of miR-149-3p
    Jiang, Zequn
    Ma, Yanxia
    Tian, Tian
    Sun, Yan
    Chen, Hao
    Lu, Ye
    Wu, Yan
    Jiang, Haiying
    Li, Wenting
    Li, Li
    Zhou, Hongguang
    Wu, Mianhua
    JOURNAL OF ETHNOPHARMACOLOGY, 2020, 258
  • [2] Jie Geng Tang reverses cisplatin resistance through the Nrf2 pathway in lung cancer
    Zhao, Jing
    Hou, Manting
    Ding, Kaixin
    Li, Shixiong
    Li, Hui
    Zhang, Xili
    Bai, Zhaofang
    Liu, Wenlong
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2023, 75 (06) : 784 - 805
  • [3] Engineered exosomes transporting the lncRNA, SVIL-AS1, inhibit the progression of lung cancer via targeting miR-21-5p
    Xu, Hao
    Ma, Hongda
    Zha, Lifen
    Li, Qian
    Pan, Huiming
    Zhang, Ladi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (07): : 3335 - 3347
  • [4] LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p
    Hua, Gang
    Zeng, Zhao-long
    Shi, Yi-ting
    Chen, Wei
    He, Li-feng
    Zhao, Guo-fang
    PHARMACOLOGY, 2021, 106 (9-10) : 498 - 508
  • [5] miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8
    Haitao Qiu
    Xiaokang Shen
    Bing Chen
    Tianming Chen
    Guodong Feng
    Shilin Chen
    Dongjie Feng
    Qiaoshu Xu
    Apoptosis, 2021, 26 : 261 - 276
  • [6] miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8
    Qiu, Haitao
    Shen, Xiaokang
    Chen, Bing
    Chen, Tianming
    Feng, Guodong
    Chen, Shilin
    Feng, Dongjie
    Xu, Qiaoshu
    APOPTOSIS, 2021, 26 (5-6) : 261 - 276
  • [7] Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway
    Qi, Kang
    Li, Yang
    Li, XueBing
    Lei, Xing
    Wang, Bo
    Zhang, LianBin
    Chu, XiangYang
    ANTI-CANCER DRUGS, 2016, 27 (10) : 970 - 978
  • [8] MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3
    Qi, M-M
    Ge, F.
    Chen, X-J
    Tang, C.
    Ma, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (12) : 5242 - 5250
  • [9] Synergistic anticancer activity of cisplatin combined with tannic acid enhances apoptosis in lung cancer through the PERK-ATF4 pathway
    Xiang Zheng
    Lei Yang
    Wei Zhai
    Nana Geng
    Zhimin Zhang
    Xueying Li
    Mingsong Wu
    European Journal of Medical Research, 28
  • [10] miR-144-3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2
    Yin, Yan
    Liu, Hua
    Xu, Junhui
    Shi, Dongsheng
    Zhai, Liang
    Liu, Bin
    Wang, Lei
    Liu, Guangxin
    Qin, Jianwen
    ONCOLOGY REPORTS, 2018, 40 (06) : 3479 - 3488